NCT03838497View on ClinicalTrials.gov

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 2, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

February 28, 2017

Conditions
Streptococcal PneumoniaHIV/AIDS
Interventions
BIOLOGICAL

Prevenar13

Prevenar13 for both arms

All Listed Sponsors
lead

Korea University Guro Hospital

OTHER

NCT03838497 - Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults | Biotech Hunter | Biotech Hunter